will tirzepatide go back on shortage list FDA says the weight-loss drug is over GLP-1 Drugs: FDA Removes Lilly's

Clinical Evidence and Alcohol Safety While there are limited direct studies on Mounjaro and alcohol, related data from GLP-1 agonists such as semaglutide provide insight

Several Phase 2 trials are currently testing semaglutide for alcohol use disorder, including studies registered as NCT05895643 and NCT05520775

But because people on semaglutide or tirzepatide lose more weight in the first place, they all end up returning to baseline at approximately the same time, study senior researcher Dimitrios Koutoukidis of Oxford University told Reuters

Semaglutide trials (STEP 1-4) demonstrated 15-22% weight loss over 68 weeks, while tirzepatide (SURMOUNT trials) showed 20-24% weight loss at the highest doses